Protocolsβ€ΊWeight Management β€” GLP-1 Protocol
BeginnerWeight Management24 weeks

Weight Management β€” GLP-1 Protocol

Achieve sustained, physiologically safe weight reduction through GLP-1 receptor agonism, appetite regulation, and metabolic optimization

Patient profile: Adults BMI β‰₯ 27 with at least one comorbidity (pre-diabetes, hypertension, dyslipidemia) or BMI β‰₯ 30, not responding adequately to lifestyle interventions alone

Want a personalised protocol?

Our AI generator builds a protocol tailored to your profile and goals.

Generate protocol β†’
⚠️

This protocol is an educational example only. It does not apply to your specific health situation. Medical supervision is required. Peptide therapy is not approved by regulatory bodies for many of the described indications.

Protocol Stack

Semaglutide

Primary

Dose

0.25 mg β†’ 0.5 mg β†’ 1.0 mg (titration)

Frequency

1x/week SC

Timing

Same day each week, any time

Duration

24 weeks (titration over first 8 weeks)

BPC-157

Optional

Dose

250 mcg

Frequency

Daily SC

Timing

Morning, fasted

Duration

First 8 weeks (supports GI tolerance)

Monitoring Parameters

  • βœ“Fasting glucose, HbA1c β€” baseline, week 8, week 24
  • βœ“Lipid panel β€” baseline and week 24
  • βœ“Body weight and waist circumference β€” weekly
  • βœ“GI symptom diary (nausea score 0–10)
  • βœ“Blood pressure β€” bi-weekly
  • βœ“Thyroid function (TSH) β€” baseline and week 24
  • βœ“Liver enzymes (AST, ALT) β€” baseline and week 12

Expected Outcomes

1

Weeks 1–4: Appetite reduction begins, possible mild nausea β€” start BPC-157 support

2

Weeks 5–8: Dose titrated to 0.5 mg; 2–4% body weight loss expected

3

Weeks 9–16: Consistent 0.5–1 kg/week loss; metabolic markers improving

4

Weeks 17–24: Stable at 1.0 mg; total 8–15% body weight reduction realistic

5

Post-protocol: Taper strategy required β€” do not stop abruptly

Contraindications

  • βœ—Personal or family history of medullary thyroid carcinoma (MTC)
  • βœ—Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
  • βœ—Active pancreatitis or history of pancreatitis
  • βœ—Severe renal impairment (eGFR < 15 mL/min)
  • βœ—Pregnancy β€” discontinue at least 2 months before planned conception

Clinical Notes

Titration is non-negotiable β€” rushing to therapeutic dose causes intolerable nausea and drops compliance. BPC-157 co-administration during the first 8 weeks measurably reduces GI side effects. Protein intake must be β‰₯ 1.6 g/kg/day and resistance training maintained to preserve lean mass during rapid weight loss.

Case Study

Clinical Practice Example

Female, 44, BMI 34.2, pre-diabetic (HbA1c 6.1%), failed two structured diet programs. Started semaglutide 0.25 mg with BPC-157 support. No nausea beyond mild discomfort in week 2. Reached 1.0 mg at week 9. At week 24: weight loss of 18.4 kg (16.2% body weight), HbA1c normalized to 5.4%, waist circumference reduced by 14 cm. Transitioned to 0.5 mg maintenance.

← Back to all protocols